AstraZeneca Pharma India
Astrazeneca Pharma India Performance
Day Range
- Low 4,726.85
- High 4,875.00
52 Week Range
- Low 3,098.00
- High 4,996.90
- Open Price4,800.00
- Previous Close4,800.55
- Volume9296
Start SIP in AstraZeneca Pharma India
Start SIPAstrazeneca Pharma India Investment Rating
-
Master Rating:
-
Astrazeneca Pharma India has an operating revenue of Rs. 1,141.05 Cr. on a trailing 12-month basis. An annual revenue growth of 25% is outstanding, Pre-tax margin of 13% is healthy, ROE of 16% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 24% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 93 which is a GREAT score indicating consistency in earnings, a RS Rating of 65 which is FAIR indicating the recent price performance, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 76 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.
EPS Strength
Price Strength
Buyer Demand
Group Rank
Indicator | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 |
---|---|---|---|---|---|---|---|
Oper Rev Qtr Cr | 311 | 295 | 285 | 250 | 236 | 232 | 232 |
Operating Expenses Qtr Cr | 258 | 228 | 225 | 213 | 195 | 204 | 194 |
Operating Profit Qtr Cr | 53 | 67 | 60 | 37 | 41 | 28 | 38 |
Depreciation Qtr Cr | 4 | 4 | 4 | 4 | 3 | 5 | 4 |
Interest Qtr Cr | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
Tax Qtr Cr | 21 | 18 | 6 | 10 | 12 | 7 | 9 |
Net Profit Qtr Cr | 52 | 54 | 17 | 29 | 33 | 20 | 28 |
Astrazeneca Pharma India Technicals
EMA & SMA

- Bullish Moving Average
- ___
- 16
- Bearish Moving Average
- ___
- 0
- 20 Day
- ₹4,718.38
- 50 Day
- ₹4,614.76
- 100 Day
- ₹4,385.47
- 200 Day
- ₹4,044.44
- 20 Day
- ₹4,713.43
- 50 Day
- ₹4,662.81
- 100 Day
- ₹4,365.14
- 200 Day
- ₹3,871.74
Astrazeneca Pharma India Resistance and Support
Resistance | |
---|---|
First Resistance | 4,896.15 |
Second Resistance | 4,959.65 |
Third Resistance | 5,044.30 |
RSI | 63.40 |
MFI | 68.96 |
MACD Single Line | 27.32 |
MACD | 38.66 |
Support | |
---|---|
First Resistance | 4,748.00 |
Second Resistance | 4,663.35 |
Third Resistance | 4,599.85 |
Astrazeneca Pharma India Delivery and Volume
Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
---|---|---|---|
Day | 9,732 | 547,717 | 56.28 |
Week | 9,533 | 578,641 | 60.7 |
1 Month | 11,212 | 529,213 | 47.2 |
6 Month | 17,061 | 868,388 | 50.9 |
Astrazeneca Pharma India Result Highlights
AstraZeneca Pharma India Synopsis
NSE-Medical-Diversified
Astrazeneca Pharma I is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 1002.97 Cr. and Equity Capital is Rs. 5.00 Cr. for the Year ended 31/03/2023. AstraZeneca Pharma India Ltd. is a Public Limited Listed company incorporated on 11/07/1979 and has its registered office in the State of Karnataka, India. Company’s Corporate Identification Number(CIN) is L24231KA1979PLC003563 and registration number is 003563.Market Cap | 12,082 |
Sales | 1,141 |
Shares in Float | 0.63 |
No of funds | 92 |
Yield | 0.33 |
Book Value | 20.52 |
U/D Vol ratio | 1.1 |
LTDebt / Equity | |
Alpha | 0.12 |
Beta | 0.43 |
AstraZeneca Pharma India
Owner Name | Sep-23 | Jun-23 | Mar-23 | Dec-22 |
---|---|---|---|---|
Promoters | 75% | 75% | 75% | 75% |
Mutual Funds | 2.42% | 1.76% | 1.22% | 1.22% |
Foreign Portfolio Investors | 2.69% | 2.68% | 2.7% | 2.61% |
Financial Institutions/ Banks | ||||
Individual Investors | 17.44% | 18.12% | 18.46% | 18.56% |
Others | 2.45% | 2.44% | 2.62% | 2.61% |
AstraZeneca Pharma India Management
Name | Designation |
---|---|
Mr. Narayan K Seshadri | Chairman & Ind.Director |
Mr. Sanjeev Kumar Panchal | Executive Director |
Mr. Rajesh Marwaha | Executive Director |
Mr. Ankush Nandra | Non Executive Director |
Ms. Shilpa Shidhar Divekar | Independent Director |
Ms. Weiying Sarah Wang | Non Executive Director |
Ms. Revathy Ashok | Independent Director |
Astrazeneca Pharma India Forecast
Price Estimates
Astrazeneca Pharma India Corporate Action
Date | Purpose | Remarks |
---|---|---|
2023-11-09 | Quarterly Results | |
2023-08-14 | Quarterly Results | |
2023-05-30 | Audited Results & Dividend | |
2023-02-10 | Quarterly Results | |
2022-11-11 | Quarterly Results |
Date | Purpose | Remarks |
---|---|---|
2023-07-14 | FINAL | Rs.16.00 per share(800%)Dividend |
2022-07-08 | FINAL | Rs.8.00 per share(400%)Final Dividend |
2021-08-20 | INTERIM | Rs.2.00 per share(100%)Interim Dividend |
AstraZeneca Pharma India FAQs
What is Share Price of AstraZeneca Pharma India ?
AstraZeneca Pharma India share price is ₹4,832 As on 06 December, 2023 | 04:22
What is the Market Cap of AstraZeneca Pharma India ?
The Market Cap of AstraZeneca Pharma India is ₹12081.6 Cr As on 06 December, 2023 | 04:22
What is the P/E ratio of AstraZeneca Pharma India ?
The P/E ratio of AstraZeneca Pharma India is 79.1 As on 06 December, 2023 | 04:22
What is the PB ratio of AstraZeneca Pharma India ?
The PB ratio of AstraZeneca Pharma India is 20.5 As on 06 December, 2023 | 04:22